Regeneron Pharmaceuticals, Inc.

REGN · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders2.1%

Institutions93.7%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$14.34B	$14.20B	$13.12B	$12.17B	$16.07B	$8.50B	$7.86B	$6.71B	$5.87B	$4.86B
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$2.10B	$1.97B	$1.82B	$1.56B	$2.44B	–	$782.20M	$416.60M	$202.51M	$194.62M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$3.58B	$3.99B	$4.05B	$4.74B	$8.95B	$3.58B	$2.21B	$2.53B	$2.08B	$1.33B
Operating income as a percentage of revenue.	24.9%	28.1%	30.9%	38.9%	55.7%	42.1%	28.1%	37.8%	35.4%	27.4%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$4.50B	$4.41B	$3.95B	$4.34B	$8.08B	$3.51B	$2.12B	$2.44B	$1.20B	$895.52M
Net income divided by the number of shares outstanding — profit attributable to each share.	$43.07	$40.90	$37.05	$40.51	$76.40	$32.65	$19.38	$22.00	$11.00	$8.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$41.48	$38.34	$34.77	$38.22	$71.97	$30.52	$18.46	$21.00	$10.00	$7.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$3.12B	$2.49B	$2.73B	$3.11B	$2.89B	$2.19B	$1.62B	$1.47B	$812.73M	$535.20M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$40.56B	$37.76B	$33.08B	$29.21B	$25.43B	$17.16B	$14.81B	$11.73B	$8.76B	$6.97B
All of the company's interest-bearing borrowings, short and long term combined.	$1.99B	$1.98B	$1.98B	$1.98B	$1.98B	$1.98B	–	–	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$9.30B	$8.41B	$7.11B	$6.55B	$6.67B	$6.14B	$3.72B	$2.98B	$2.62B	$2.52B
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$31.26B	$29.35B	$25.97B	$22.66B	$18.77B	$11.03B	$11.09B	$8.76B	$6.14B	$4.45B

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$4.98B	$4.42B	$4.59B	$5.01B	$7.08B	$2.62B	$2.43B	$2.20B	$1.31B	$1.47B
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$898.40M	$755.90M	$718.60M	$590.10M	$551.90M	$614.60M	$429.60M	$383.10M	$272.63M	$511.94M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$4.08B	$3.66B	$3.88B	$4.42B	$6.53B	$2.00B	$2.00B	$1.81B	$1.03B	$961.46M

	You	Peer avg
P/E	20.0	47.8
Revenue Growth	+16.7%	+1147.3%
ROE	14.0%	3.3%

Regeneron Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison